ro glp 1 insurance coverage LAUNCHES WEGOVY® PILL THROUGH INTEGRATION WITH NOVO NORDISK Ro CEO talks new GLP-1

Competitive Landscape GLP-1 Weight Loss Drug Market Competitive Landscape: Novo Nordisk and Eli Lilly Duopoly, Oral GLP-1 Challengers, and Telehealth Platforms Reshape the Obesity Drug Market Through 2035 The GLP-1 Weight Loss Drug Market competitive landscape is defined by exceptional concentration at the approved drug tier where Novo Nordisk and Eli Lilly collectively control approximately 87% of global prescription obesity drug revenue combined with intense clinical development competition among more than 40 active GLP-1 pipeline programs

Prices listed above are before any taxes or promotional discounts

Here is what typically factors in

Have documentation accessible but not necessarily in hand

Newer dual-hormone drugs like tirzepatide have since pushed the averages higher, toward 20%